Overage

Overage is the deliberate excess of active ingredient added at formulation so the finished product still meets label claim at the end of its labelled shelf life, after every quantifiable manufacturing loss and every quantifiable degradation pathway has been accounted for. It is a controlled, justified, change-controlled, dossier-cited number — typically expressed as a percentage above label claim (e.g. 'label claim 500 mg, overage 3%, formulation target 515 mg').

Overage is decomposed into two additive components. Manufacturing overage covers losses during the process — adsorption to filters, retention in mixing-vessel dead legs, splash at fill, lyophiliser shelf retention, residue after wash — and is bounded by the validated loss profile of the equipment train. Stability overage covers first-order degradation across the labelled shelf life at the labelled storage condition, derived from ICH Q1A(R2) stability data. Each component must be justified, costed, and dossier-cited separately. Adding the two without decomposition is the most common audit observation in overage governance.

The two components are independent and must be calculated, justified, and tracked as separate numbers in the MMR. Mixing them — quoting a single 'overage = 3.5%' figure without showing the split — is the failure mode that lets a stability problem hide inside a manufacturing-loss assumption (or vice versa).

When multiple corrections apply — salt-to-base conversion, LOD/water compensation, potency factor, and overage — the order of operations determines whether the product delivers label claim or drifts ±2%. The canonical sequence, derived from EMA's reflection paper §3 and FDA Process Validation guidance:

1. Start from label-claim quantity per dosage unit × planned batch dose count → label-claim mass per batch (the contract with the patient).
2. Add stability overage as a percentage of label-claim mass → end-of-shelf-life target mass.
3. Add manufacturing overage as a percentage of end-of-shelf-life target mass → as-formulated target mass (the figure the operator would weigh if the active were 100% reference potency on the as-charged basis).
4. Apply salt-to-base conversion factor (multiply by MW(salt)/MW(base) if the API is salt-form and label claim is free base) → as-formulated salt-mass target.
5. Apply anhydrous-basis correction (divide by 1 − LOD) if formula and assay are on different moisture bases → as-charged target on the assay basis.
6. Apply potency factor (multiply by reference / measured) → adjusted-as-charged target. This is the figure the operator weighs to.
7. Recompute counter-balance excipient so total batch mass holds → the diluent's adjusted target. The kiosk shows the operator both numbers.

Overage is one of the few formulation decisions where the regulatory texts are explicit about an upper bound, even if no numeric cap is written into US law. The ceiling is set by the burden of proof shifting steeply as overage rises.

Stability overage is derived from primary stability data following first-order or pseudo-first-order kinetics. The headline equation is C(t) = C₀ · e^(−k·t), where k is the rate constant at the labelled storage temperature and t is the labelled shelf life. The overage that guarantees label claim at end-of-shelf-life with confidence is set so C(t_shelf) ≥ C_label_claim × tolerance_floor (typically 95% per USP <905>).

Worked example: an oral solid with k = 0.018 / year at 25°C/60% RH (from 24-month primary stability), 24-month shelf life, label claim 500 mg, tolerance floor 95% (475 mg). C(24) / C₀ = e^(−0.018 × 2) = 0.9646. To keep C(24) ≥ 475 mg, C₀ must be ≥ 475 / 0.9646 = 492.45 mg, i.e. stability overage = 492.45 / 500 − 1 = −1.51% (negative — the product is stable enough that no stability overage is needed, only a small manufacturing overage to cover splash and adsorption).

A more reactive molecule with k = 0.054 / year at 25°C/60% RH and 36-month shelf life: C(36) / C₀ = e^(−0.054 × 3) = 0.850. To keep C(36) ≥ 475 mg, C₀ ≥ 559 mg, stability overage = 11.7% — well into the EMA 'must be the exception' band and requiring detailed Module 3 justification, or shorter shelf life, or refrigerated storage to lower k, or reformulation. The math is the forcing function for those reformulation decisions, not a free pass to add 12% active.

Manufacturing overage is bounded by the validated equipment-train hold-up. The standard derivation runs across the three PPQ batches: for each step, in-process mass balance (theoretical mass in vs theoretical mass out, accounting for water, solvent, evaporation, in-process samples) is computed, and the persistent loss across all three batches is the validated loss for that step. The sum of step losses, expressed as a percentage of the formulated batch mass, is the manufacturing overage ceiling.

• Tubing/filter adsorption — measured by pre/post mass balance of the filter assembly; typically 0.05–0.3% for solid-dose granulation, 0.5–2% for sterile fill (vent filters), up to 5% for protein-drug filter trains.
• Mixing-vessel dead leg / wall retention — measured by rinsing the empty vessel post-discharge and assaying the rinse; typically 0.1–1% for solid-dose, higher for sticky liquids.
• Fill loss / splash — measured by mass balance pre/post filling station; typically 0.5–3% for liquids, 0.1–0.5% for solid-dose.
• Lyophiliser shelf retention — measured by mass balance pre/post lyo cycle; typically 1–4% for protein and small-molecule lyo products.
• Wash-down recovery — what isn't washed down is part of the loss; cleaning validation provides the data.
• In-process sample mass — every IPC sample is loss; must be accounted for explicitly, not absorbed into overage by default.

Dietary supplements (21 CFR 111) operate under similar logic but with a more permissive ceiling — vitamins and minerals routinely carry 5–15% overfill because of well-characterised stability decay (vitamin C, B-vitamins, methylcobalamin), and the label claim is 'X mg per serving' with the regulatory expectation that the product meets that claim through the labelled best-before date. The mechanic is identical: split the overfill into stability and manufacturing components, justify each in the MMR, capture both in the BMR. The acceptable upper bound is wider but is not unlimited — labelling fraud (overfilling to allow a smaller potency label claim than the actual product, to reduce regulatory burden) is an FTC issue separate from the 111 framework.

Food fortification (21 CFR 104, 21 CFR 184/186 for GRAS substances, USDA Food Composition databases for natural matrix) treats overage similarly — the label '120 mg vitamin C per serving' contract is met through shelf life, with the overage justified by a documented stability programme. The supply chain implication is significant: a fortified breakfast cereal with 25% vitamin overfill at production has to honour that figure at the retail expiry date 12+ months later, after warehouse temperature excursions, after transit, after retail shelf time.

Vitamin and mineral premix blending — where the overfill decision is operationally made — is one of the most error-prone steps in supplement manufacturing because the premix vendor's overfill (added at their site) compounds with the manufacturer's overfill (added at the finished-product blend), and double-counting is the most common 483 in 111.260 records audits.

1. Overage used to mask un-investigated yield loss — the textbook §211.100 / §211.103 violation. Yield dropped, overage 'absorbed' the loss, the deviation was never opened. Warning letters cite this every quarter.
2. Combined overage quoted without decomposition — single 'overage = 4%' figure that cannot be reconciled to either stability or PPQ data. EMA reflection paper §4 specifically calls this out.
3. Stability overage based on accelerated data only — real-time data not yet supportive, but the MMR cites the larger number anyway. Lasts until the first stability surveillance reveals the gap.
4. Premix double-counting in supplements — premix vendor includes 15% overfill, manufacturer adds another 10%, finished product is 26% over label claim and fails USP <2091> upper limits.
5. Overage retained after process improvement — formulation team eliminated a loss step, overage was never re-justified down. Product chronically over-strength, drifts toward USP upper limit, eventually fails.
6. Salt-to-base mismatch with overage — overage applied to label-claim mass without first converting to salt-form mass, finished product under-strength by the conversion factor minus the overage.
7. Stability overage exceeded by real-time decay — degradation rate higher than primary stability predicted, batches released against shorter shelf life ad-hoc rather than re-justifying overage under change control.
8. Justification artefact missing or stale — MMR cites 'PPQ Report 2019-04' that has been superseded twice and the current overage no longer reconciles to the cited document. Found on every records audit.

• Combined overage % by SKU — distribution across the portfolio (flag any SKU >5% for re-justification review, any SKU >10% for reformulation feasibility).
• Manufacturing vs stability split % — every active should have both numbers separately. Quoting only the combined number is a process-discipline regression.
• Justification-artefact currency — % of formulas where the cited PPQ report and stability study are the current effective version (target 100%, audited quarterly).
• Actual loss vs validated loss variance — across batches, is actual manufacturing loss tracking the validated figure? Drift upward triggers PPQ revalidation, not a higher overage.
• Actual stability vs predicted decay — surveillance stability points should sit within the prediction interval of the dossier curve. Excursions trigger deviation, not an overage increase.
• Overage-driven deviation rate — % of batches where actual loss or actual decay exceeded the justified overage and a deviation was opened (this should be a small but non-zero number; zero suggests deviations are being suppressed).
• Premix double-count audit — for supplement products, % of premix-derived actives where the cumulative overfill (vendor + manufacturer) is reconciled in the MMR (target 100%).

1. Formula schema: every active row carries label_claim_qty, overage_mfg_pct, overage_stability_pct (both nullable but encouraged), and two link fields (justification_mfg_ref to PPQ report, justification_stability_ref to stability study) — neither number can be set without its link.
2. MMR approval gate: the two-person e-signature contract (preparer + independent reviewer) explicitly displays the justification documents; reviewer cannot approve without acknowledging both.
3. MMR snapshot on WO release: the overage figures and their justification references are copied into work_orders.mmr_snapshot, locking the version of the justification active for that batch.
4. Kiosk dispense sequence: shows the label-claim mass → +stability overage → +manufacturing overage → as-formulated target, then layers SBF / LOD / PF on top with the full math visible. Operator sees seven numbers, weighs to the last.
5. BMR rendering: prints the seven-step sequence per dispense, plus the cited justification dossier titles + effective dates, so a regulator can reconstruct the math from the BMR alone.
6. Yield reconciliation gate: at batch close, actual loss per step (from in-process samples) is compared to the validated loss from the PPQ report. If actual > validated, a deviation auto-opens — no 'overage absorbed it' shortcut.
7. Change control: any change to overage_mfg_pct or overage_stability_pct routes through change control with mandatory justification update, MMR version bump, and CSV impact assessment.
8. Premix reconciliation: for supplement formulas, the kiosk shows premix-derived actives with their inherited vendor overfill alongside the formulation overfill, and the BMR flags any cumulative-overfill cell that exceeds USP <2091> ceilings.
9. Periodic review: the regulated-reports module includes an overage-currency report — every SKU, both percentages, last justification effective date, last surveillance stability data point — that QA reviews quarterly per ICH Q10 §3.2.5.
10. Audit trail: every overage change carries the old value, new value, reason, supporting document reference, and approver chain — ALCOA+ compliant per Part 11 §11.10(e).

See the FAQs below for short answers on common operational questions — when overage is mandatory, how it interacts with USP tolerance, how overfill in sterile vials differs from solid-dose overage, and how to handle overage in a continuous-manufacturing process.